HOUSTON, November 12, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025. Recent… Read More..

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results PDF Version – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to… Read More..

SKYX Positions to Advance its Market Penetration with the AI Native E-Commerce Platform Designed to Elevate B2B and B2C Experiences Through its Innovative and Smart Product Line SKYX Continues to Grow its Builder Segment Through Direct Sales Channels and Intends to Utilize the New AI Driven Software to Enhance and… Read More..